EPO-TRAUMA Trial

ErythroPOietin alfa to prevent mortality and reduce severe disability in critically ill TRAUMA patients: a multi-centre, stratified, double-blind, randomised, placebo-controlled trial. (The EPO-TRAUMA trial)

ErythroPOietin alfa to prevent mortality and reduce severe disability in critically ill TRAUMA patients

Sites36
Patients910

Committee
Contacts
Progress

Study Progress

Country	Recruited
Australia	497
New Zealand	176
Finland	85
Switzerland	59
Saudi Arabia	47
Ireland	31
Slovenia	12
Belgium	2
Germany	1
Total	910